Show simple item record

dc.contributor.authorDong, Lanfeng
dc.contributor.authorNeuzil, Jiri
dc.date.accessioned2019-11-04T04:59:21Z
dc.date.available2019-11-04T04:59:21Z
dc.date.issued2019
dc.identifier.issn2523-3548
dc.identifier.doi10.1186/s40880-019-0412-6
dc.identifier.urihttp://hdl.handle.net/10072/388890
dc.description.abstractMitochondria are organelles controlling adenosine triphosphate (ATP) generation, redox homeostasis, metabolic signaling, and apoptotic pathways. Although glycolysis was traditionally considered as the major source of energy in cancer cells, in-line with the so-called “Warburg effect”, mitochondria have been recognized to play a key role in oncogenesis [1]. Cancer cells uniquely reprogram their cellular activities to support their rapid proliferation and migration, as well as to counteract metabolic and genotoxic stress during cancer progression [2]. Further, mitochondria can switch their metabolic phenotypes to meet the challenges of high energy demand and macromolecular synthesis [3]. Thus, cancer mitochondria have the ability to flexibly switching between glycolysis and oxidative phosphorylation (OXPHOS) for their survival. The electron transport chain (ETC) function is pivotal for mitochondrial respiration, which is also needed for dihydroorotate dehydrogenase (DHODH) activity that is essential for de novo pyrimidine synthesis [4]. Recent researches have demonstrated that cancer cells devoid of mitochondrial DNA (mtDNA) lack their tumorigenic potential, and they re-gain this ability by acquiring healthy mtDNA from the host stromal cells via horizontal transfer of whole mitochondria [5, 6] for recovery of the respiratory function. Functionally, respiration propels DHODH activity for pyrimidine biosynthesis [7]. Therefore, targeting mitochondria holds great potential for anticancer strategy with high therapeutic opportunities.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherBioMed Central Ltd.
dc.publisher.placeUnited Kingdom
dc.relation.ispartofpagefrom63: 1
dc.relation.ispartofpageto63: 3
dc.relation.ispartofissue1
dc.relation.ispartofjournalCancer Communications
dc.relation.ispartofvolume39
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchcode3211
dc.titleTargeting mitochondria as an anticancer strategy
dc.typeJournal article
dc.type.descriptionC2 - Articles (Other)
dcterms.bibliographicCitationDong, L; Neuzil, J, Targeting mitochondria as an anticancer strategy, Cancer Communications, 2019, 39 (1), pp. 63: 1-63: 3
dcterms.licensehttp://creativecommons.org/licenses/by/4.0/
dc.date.updated2019-10-31T01:48:48Z
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
gro.hasfulltextFull Text
gro.griffith.authorNeuzil, Jiri


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record